Why the study?
The adverse event profile of COVID-19 vaccines is becoming more apparent with time, and prospective clinical trials are needed to determine if specific populations, such as those with a history of autoimmune disease, face higher risks.
Prospective clinical trials are needed to determine whether specific populations are at higher risk of developing adverse events from COVID-19 vaccines.
Leaves open differential COVID-19 vaccine risk by subgroup; prospective trials needed before any practice change.
The COVID-19 pandemic has caused millions of deaths and has affected most people across the world, either directly or indirectly. Many preventative and therapeutic strategies have been employed since the beginning of the pandemic. With the development of the mRNA vaccine within a year of the start of the pandemic, we are entering a new era of vaccinology, and the adverse event profile of the COVID-19 vaccine is also becoming more apparent with time. While the benefits of the vaccines and other preventative strategies certainly outweigh the risk of adverse events, prospective clinical trials are urgently needed to determine whether specific populations, including those with a personal or family history of autoimmune disease, are at higher risk of developing certain adverse events, in order to minimize risk further.
No takes yet. Share an insight, caveat, or question.
Kunal Ajmera (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: